Latest Breaking News On - Data safety monitoring board - Page 8 : comparemela.com

BioMedNewsBreaks – CNS Pharmaceuticals Inc (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

BioMedNewsBreaks – CNS Pharmaceuticals Inc (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesJohn climacoPharmaceuticals incLife sciencesCns pharmaceuticalsBiomedical sciences biomedData safety monitoring boardBiomedical sciencesDynamic brand portfolioPhones only

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLance alstodtBiorestorative therapies incExchange commissionMetabolic program thermostemDisc spine programTrademark officeSecurities exchangeOrthopaedic research societyRestorative therapiesRecent pipelineData safety monitoring boardVisual analog scaleOswestry disability indexRoland morris disability questionnaireFunctional rating index

BioCardia, Inc (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11.

United statesDavid mcclungPeter altmanBrent pearsonJoe smithMiranda petoLargest airport companiesSam clubDevice agencyBiocardia incCall transcript marchEnd financial resultsBusiness update conferenceBiocardia investorChief executive officerChief financial

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Cli

Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in first half of 2025Clinical progress represents important steps towa.

United statesJohn climacoAmy maheryJenene thomasPharmaceuticals fast track designation for berubicinSecurities exchangeCompany on twitterBerubicin clinical development progressCompany board of directorsExchange commissionPharmaceuticals incData safety monitoring boardOverall survivalFinancial resultsFull yearFast track designation

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights .

United statesAmy maheryJohn climacoPharmaceuticals incNews networkCompany board of directorsPharmaceuticals fast track designation for berubicinBerubicin clinical development progressData safety monitoring boardClinical development progress theOverall survivalFinancial resultsFull yearFast track designationOrphan drug designation